SCHEMBL19862428

SCHEMBL19862428

Cc1cc(C(C)C)nc(OC2CCCC2)n1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 2/20 0.41
PDE9A O76083 1/20 0.36
PDGFRB P09619 3/20 0.36
PDGFRA P16234 3/20 0.36
FFAR4 Q5NUL3 1/20 0.35
CDK1 P06493 1/20 0.35
CDK2 P24941 1/20 0.35
CDK7 P50613 1/20 0.35
CDK9 P50750 1/20 0.35
CDK6 Q00534 1/20 0.35
CDK5 Q00535 1/20 0.35
LRRK2 Q5S007 1/20 0.35
PTGS1 P23219 5/20 0.34
GRM5 P41594 5/20 0.34
LDHA P00338 1/20 0.34
NOS3 P29474 1/20 0.33
NOS1 P29475 1/20 0.33
NOS2 P35228 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19865016 0.81 GRM5 (0.40) PDE9ALRRK2GRM5
SCHEMBL3410707 0.77 CDK4 (0.40) CDK4PDGFRBPDGFRAFFAR4CDK1
SCHEMBL19899744 0.76 FFAR4 (0.41) CDK4PDGFRBPDGFRAFFAR4LRRK2
SCHEMBL11788449 0.75 GRM5 (0.42) CDK4PDGFRBPDGFRAFFAR4CDK1
SCHEMBL16116472 0.74 ACACB (0.42) CDK4CDK1CDK2CDK7CDK9
SCHEMBL19510918 0.73 FFAR4 (0.39) CDK4PDGFRBPDGFRAFFAR4LRRK2
SCHEMBL12351912 0.73 NOS3 (0.39) NOS3NOS1NOS2
SCHEMBL31426424 0.73 PDE2A (0.39) CDK4PDGFRBPDGFRAFFAR4LRRK2
SCHEMBL26618046 0.73 PDE2A (0.39) CDK4PDGFRBPDGFRAFFAR4LRRK2
SCHEMBL20355536 0.73 CDK4 (0.43) CDK4PDGFRBPDGFRACDK1CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180044338-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC (US) 2018-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180044338-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 CDK4 1330/4885PDE9A 2060/4885PDGFRB 2694/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.